{
    "Trade/Device Name(s)": [
        "HemosIL D-Dimer"
    ],
    "Submitter Information": "Instrumentation Laboratory Co.",
    "510(k) Number": "K073042",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070927",
        "K050278"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DAP"
    ],
    "Summary Letter Date": "July 31, 2008",
    "Summary Letter Received Date": "June 30, 2008",
    "Submission Date": "June 27, 2008",
    "Regulation Number(s)": [
        "21 CFR 864.7320"
    ],
    "Regulation Name(s)": [
        "Fibrinogen/Fibrin Degradation Product Assay"
    ],
    "Analyte Class(es)": [
        "hematology",
        "coagulation"
    ],
    "Analyte(s)": [
        "D-Dimer"
    ],
    "Specimen Type(s)": [
        "Citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "IL Coagulation Systems",
        "ACL TOP",
        "ACL ELITE",
        "ACL Family",
        "ACL Futura",
        "ACL Advance"
    ],
    "Method(s)/Technology(ies)": [
        "Latex enhanced immunoassay",
        "Turbidimetric immunoassay"
    ],
    "Methodologies": [
        "Immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL D-Dimer latex enhanced immunoturbidimetric assay for quantitative D-Dimer determination in citrated plasma on IL Coagulation Systems",
    "Indications for Use Summary": "Automated latex enhanced immunoassay for quantitative determination of D-Dimer in human citrated plasma to aid in excluding venous thromboembolism in outpatients suspected of deep venous thrombosis and pulmonary embolism, used with a clinical pretest probability assessment model",
    "fda_folder": "Hematology"
}